Junshi Bio (01877) rose more than 4%, reaching 4.03% as of press time, at HK$19.09, with a turnover of HK$23.2684 million.

On the news front, according to Junshi Bio's official WeChat account, the company announced that it has officially signed a strategic cooperation agreement with Meijie Medical recently. The two parties will carry out comprehensive strategic cooperation around core directions such as "multimodal thermophysical immune regulation platform technology and drug combination clinical research, and new drug target exploration," leading cancer treatment into a new era of "multimodal drug-device combination."

The focus of this cooperation is to break traditional industry boundaries, systematically integrate local precision intervention with systemic immune activation, and build a new treatment model of "interventional immunity." The two parties will focus on the launch of joint clinical research and data accumulation, clarifying the efficacy and safety characteristics of the combination regimen in target indications; exploring the feasibility of obtaining regulatory approval for "drug-device combination" regimens and forming a replicable registration and commercialization path; and hoping to expand this model to more tumor types and treatment combinations, promoting "drug-device combination" to become one of the standard options for cancer treatment, while exploring the possibility of extending to overseas markets.